Drug Profile

Diclofenac vaginal - Dare Bioscience

Alternative Names: DARE-PDM1

Latest Information Update: 30 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dare Bioscience
Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
Mechanism of Action Cyclooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Dysmenorrhoea

Most Recent Events

30 Jan 2025 Phase-I clinical trials in Dysmenorrhoea in Australia(Vaginal) (Dare Biosciences pipeline, January 2025)
20 Dec 2023 Efficacy, adverse events and pharmacokinetics data from the phase I DARE-PDM1-001 trial in Dysmenorrhoea released by Dare Bioscience
09 Mar 2023 Dare Bioscience plans a phase I trial for Dysmenorrhea in 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com